Dosing regimen for Anti-DLL3 agents
TW202629612APending Publication Date: 2026-07-16AMGEN INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114145527
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-09-14
- Filing Date
- 2020-11-05
- Publication Date
- 2026-07-16
Abstract
The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent at a dose of between about 0.3 mg to about 100 mg or between about 3 mg to about 200 mg, once every two weeks. Step dosing of the anti-DLL3 agent for the treatment of SCLC is also disclosed.
Need to check novelty before this filing date? Find Prior Art